Cargando…

Cost and carbon burden of long-acting injections: a sustainable evaluation

Aims and method This study explores the economic cost and carbon footprint associated with current patterns of prescribing long-term flupentixol decanoate long-acting injections. We conducted an analysis of prescription data from a mental health trust followed by economic and carbon cost projections...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maughan, Daniel L., Lillywhite, Rob, Cooke, Matthew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Royal College of Psychiatrists 2016
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887730/ https://www.ncbi.nlm.nih.gov/pubmed/27280033 http://dx.doi.org/10.1192/pb.bp.114.049080

Ejemplares similares

Evaluating sustainability: a retrospective cohort analysis of the Oxfordshire therapeutic community
por: Maughan, Daniel, et al.
Publicado: (2016)

Minimising carbon and financial costs of steam sterilisation and packaging of reusable surgical instruments
por: Rizan, Chantelle, et al.
Publicado: (2021)

Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic
por: Chue, Pierre
Publicado: (2007)

The cost associated with administering risperidone long-acting injections in the Australian community
por: Dalton, Andrew, et al.
Publicado: (2011)

An international perspective on the acceptability and sustainability of electroconvulsive therapy
por: Maughan, Daniel, et al.
Publicado: (2016)

Reducing non-attendance rates in community psychiatry: a case for sustainable development?
por: Maughan, Daniel L., et al.
Publicado: (2015)

Social sustainability and mental health: a threat to evidence-based practice?
por: Maughan, Daniel, et al.
Publicado: (2016)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

The Effect of Switching to Long-Acting Injection (LAI) Antipsychotic Therapy on Patients with Schizophrenia
por: STRUNOIU, LIVIA MIHAELA, et al.
Publicado: (2021)

Evaluation of a long‐acting injectable formulation of omeprazole in healthy dogs
por: Odunayo, Adesola, et al.
Publicado: (2022)

Inpatient prescribing patterns of long-acting injectables and their oral or short-acting injectable equivalent formulations
por: Liu, Yifei, et al.
Publicado: (2023)

Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
por: Bakshi, Rahul P., et al.
Publicado: (2018)

Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections
por: Debaveye, Sam, et al.
Publicado: (2019)

Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
por: Druais, Sylvain, et al.
Publicado: (2016)

Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection
por: Asseburg, Christian, et al.
Publicado: (2012)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

Inspirational chemistry of bioabsorbable long-acting injectables
por: Tice, Thomas
Publicado: (2022)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting
por: Hodgson, Richard E
Publicado: (2019)

Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077
por: Tolley, Elizabeth E., et al.
Publicado: (2020)

Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database
por: Voss, Erica A., et al.
Publicado: (2015)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

A Long-Acting Thermoresponsive Injectable Formulation of Tin Protoporphyrin Sustains Antitubercular Efficacy in a Murine Infection Model
por: Adeleke, Oluwatoyin A., et al.
Publicado: (2020)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting [Corrigendum]
Publicado: (2019)

Long-Acting Injectable Naltrexone for the Management of Patients with Opioid Dependence
por: Kjome, Kimberly L., et al.
Publicado: (2011)

Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study
por: Adelman, Daphne T, et al.
Publicado: (2012)

Preparation and in vitro/in vivo evaluation of PLGA microspheres containing norquetiapine for long-acting injection
por: Park, Chun-Woong, et al.
Publicado: (2018)

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
por: Singh, Dhiren, et al.
Publicado: (2009)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: Lindenmayer, JP
Publicado: (2010)

Pharmacokinetics of olanzapine long-acting injection: the clinical perspective
por: Heres, Stephan, et al.
Publicado: (2014)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

Long-acting injectable antiretrovirals for HIV treatment and prevention
por: Spreen, William R., et al.
Publicado: (2013)

Population pharmacokinetics and dosing of long-acting injectable antipsychotics
por: Kim, David D., et al.
Publicado: (2021)

Long-acting injectable antipsychotics during pregnancy: An update
por: Paraschakis, A., et al.
Publicado: (2021)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
por: Citrome, Leslie
Publicado: (2009)

Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia
por: Kamei, Hiroyuki, et al.
Publicado: (2020)

Alternative initiation regimen of paliperidone palmitate long-acting injectable
por: Menendez Gil, I.E., et al.
Publicado: (2022)

Modeling the health impact and cost threshold of long-acting ART for adolescents and young adults in Kenya
por: Culhane, Jessica, et al.
Publicado: (2020)

A study on blood pressure changes following Olanzapine Long Acting Injection (LAI) in schizophrenia
por: Gakkhar, Shivam, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4a54laj8bcg82vbjbp6948olke